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December 29, 2009/January 5, 2010:77–81ate. As I arrived, a technician was warming up the ultrasound
achine just as Dr. Clyde and 3 assistants arrived by ambulance with
inda on a stretcher, anesthetized with ketamine. Bonobos are well
nown for their “human” characteristics, their communication skills
nd expressions of empathy, and their exuberant sexuality. They have
een conditioned to voluntarily submit to some medical procedures.
lthough bonobos are phylogenetically Homo sapiens’ closest rela-
ive, they are wild animals who will bite each other or their keepers.
hey must be placed under general anesthesia for extensive examina-
ions or treatment. General anesthesia is risky and unpleasant for the
onobos and is only used when essential.
A quick ultrasound examination showed markedly reduced left
entricular function with anteroapical thinning and dyskinesis, ascites,
nd large bilateral pleural effusions. Blood pressure was 90/60 mm
g. The electrocardiogram showed frequent premature ventricular
omplexes. Serum creatinine was 1.4 mg/dl. Serum potassium was
lightly elevated. Enzymes were consistent with passive hepatic
ongestion.
Linda’s overall condition seemed to improve slightly after thora-
entesis of 250-ml straw-colored fluid, but her cardiovascular and
espiratory function remained tenuous. Dr. Victoria Clyde, a zoo
eterinarian who has worked with the bonobos for many years,
onvened a “family” conference with the head primate curator and
everal zookeepers. Many of the treatments available to humans, such
s intensive nursing care, intravenous inotropic therapy or mechanical
irculatory assist, myocardial revascularization, and heart transplanta-
ion are simply not feasible for bonobos. Issues of prognosis, quality of
ife, and the compassion of those caring for Linda Bonobo were
imilar.
As Linda was unable to return to living independently in the
onobo quarters, and there were no other reasonable options, she was
uthanized. Post-mortem examination showed extensive coronary
therosclerosis and an extensive, old anteroapical myocardial
nfarction.
Linda Bonobo will be sorely missed by zoo staff and visitors, and
specially by the 21 remaining members of the bonobo colony,
here Linda served as a matriarch for 14 years.
Samuel Wann, MD
Chairman, Department of Cardiovascular Medicine
isconsin Heart Hospital
0000 Bluemound Road
ilwaukee, Wisconsin 53226
-mail: samuelwann@gmail.com
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erfusion Cardiovascular
agnetic Resonance in the
linical Scenario of Patients
ith Coronary Artery Disease
n the recent paper by Patel et al. (1), the investigators stated that
ardiovascular magnetic resonance (CMR) and coronary multislice
omputed tomography angiography “do not currently provide
nformation on ischemic burden and are not assumed to be presentn the clinical scenarios;” in other words, they are not suitable to
ssess appropriateness of indications for coronary revascularization.
An increasing amount of literature supports the clinical appli-
ation of stress CMR (performed with adenosine/dipyridamole, or
ore frequently, dobutamine infusion) in patients with coronary
rtery disease (CAD) (2–4). Perfusion CMR has been validated
gainst positron emission tomography and quantitative coronary
ngiography in patients with ischemic heart disease (5,6). Schwit-
er et al. (5) demonstrated a sensitivity and specificity of 91% and
4% versus positron emission tomography and of 87% and 85%
ersus quantitative coronary angiography. A myocardial perfusion
eserve index derived by perfusion CMR images can distinguish
etween normal subjects and patients with CAD (7–10). Nandalur
t al. (11) recently conducted a meta-analysis of 37 studies on the
iagnostic efficacy of stress CMR in the detection of CAD and
oncluded that stress CMR, using either vasodilator or dobut-
mine, had high sensitivity and specificity for the diagnosis of
AD.
Possible advantages of perfusion CMR over myocardial perfu-
ion scintigraphy include higher resolution imaging that discrim-
nates between subendocardial and transmural perfusion defects,
nd no need for additional radiation burden in patients who are
ften in need of subsequent angioplasty (12). The MR-IMPACT
Magnetic Resonance Imaging for Myocardial Perfusion Assess-
ent in Coronary Artery Disease Trial) multicenter study recently
emonstrated that CMR perfusion has similar, if not superior,
iagnostic performance to myocardial perfusion scintigraphy in the
etection of CAD (13). Although myocardial perfusion scintigra-
hy is a robust technique with extensive prognostic data, there is
ow increasing evidence of the prognostic value of stress CMR in
atients with known or suspected CAD (14–18).
Both the American College of Cardiology Foundation/
merican Heart Association’s 2005 Clinical Competence State-
ent on Cardiac Imaging with Computed Tomography and
MR and the 2008 Training Statement on Multimodality Non-
nvasive Cardiovascular Imaging published in previous issues of the
ournal refer to perfusion CMR as a valid clinical diagnostic tool
or guidance of coronary revascularization therapy (19,20).
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arlo Di Mario, MD, PhD
Dudley J. Pennell, MD
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125–46. reclining In-Hospital Mortality
nd Increasing Heart Failure
ncidence in Elderly Patients
ith First Myocardial Infarction
zekowitz et al. (1) report a decreasing overall mortality rate but an
ncreasing incidence of heart failure (HF), especially late-onset
F, in a large cohort of patients with a first myocardial infarction
n Alberta between 1994 and 2000. They found that in most
atients (76%) who had suffered a myocardial infarction, HF
eveloped. We have published similar data from the United
ingdom in patients from a single, large hospital service who had
first or recurrent myocardial infarction in 1998 (2), and reported
hat in 63% HF developed over the subsequent 6 years. Interest-
ngly, we reported that 84% of those who died during follow-up
rst developed HF. Recalculation of data provided by Ezekowitz et
l. (1) yields a similar figure (92%) in a somewhat older population
Fig. 1). However, some disparity does exist. Whereas Ezekowitz
t al. (1) suggest a relatively modest increase in 5-year mortality in
hose in whom HF developed, our data suggest a striking differ-
nce (Table 1). This most likely reflects differences in diagnostic
riteria. We defined HF as intervention with diuretic agents for
ymptoms or signs of HF; Ezekowitz et al. (1) used hospital codes
nd billing information, and 25% of patients coded as HF
eceived diuretic agents.
The high proportion of patients in whom HF develops after a
yocardial infarction might seem surprising because ischemic
eart disease is common and the prevalence of HF is only about
% (3). This reflects the poor prognosis of HF and suggests that
he burden of HF may be better described by its incidence rather
han prevalence (4). HF is also often under-represented in health
are statistics because events such as death or hospitalization are
scribed to the cause of HF rather than to its presence. Death is
sually a complex process, and attributing death to only one reason
ften is inappropriate. For instance, a patient could die of a lethal
rrhythmia in the setting of worsening HF induced by a recurrent
schemic event. This patient died as a consequence of a constella-
ion of events. What is important is to identify which interventions
ight produce worthwhile benefits for patients.
Clearly, reducing the incidence of HF is an important goal of
reating myocardial infarction because it may improve well-being
s well as extend life. In most patients in whom HF develops after
myocardial infarction, it occurs shortly after an initial or recurrent
oronary event, suggesting these as possible therapeutic targets.
owever, treatment with aspirin (5), statins (6), or revasculariza-
ion (7) have so far all proved disappointing in randomized trials of
atients with chronic HF, although these data should not be
xtrapolated to acute care of myocardial infarction. More attention
eeds to be paid to HF as an end point in trials of treatment for
yocardial infarction. Because HF is often a difficult and subjec-
ive diagnosis, trials need to develop standard objective criteria,
ossibly including measurement of natriuretic peptides and the
equirement for therapy with loop diuretic agents.
